NG
ALNY icon

Norden Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Norden Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$539K Buy
1,792
+239
+15% +$72.1K 0.04% 353
2026
Q1 		$514K Buy
1,553
+363
+31% +$124K 0.05% 321
2025
Q4 		$473K Sell
1,190
-221
-16% -$97.8K 0.05% 346
2025
Q3 		$643K Buy
+1,411
New +$575K 0.07% 287

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norden Group's ALNY Position: Q2 2026 in Review

Norden Group increased its Alnylam Pharmaceuticals (ALNY) stake by 15% in Q2 2026, buying an estimated $72.1K and bringing the position to 1,792 shares worth $539K. The position accounts for 0.04% of the portfolio, ranked #353.

Norden Group first reported a position in ALNY in Q3 2025 and has held it in 4 quarters since. The position peaked at $643K in Q3 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Norden Group held 1,792 shares of Alnylam Pharmaceuticals worth $539K as of Q2 2026.
  • Norden Group bought 239 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $72.1K.
  • Alnylam Pharmaceuticals made up 0.04% of Norden Group's portfolio in Q2 2026, its #353 holding.
  • Norden Group first reported a position in Alnylam Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Norden Group's Alnylam Pharmaceuticals position peaked at $643K in Q3 2025.
  • 785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Norden Group's 13F filing for Q2 2026, filed 29 Jul 2026.